A focused text on a major treatment problem in gynecologic cancer
Written by experts in the field
Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Therapy for Ovarian Cancer have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training, oncologists and basic and translational scientists in training.
Content Level » Professional/practitioner
Keywords » Appendiceal Cancer - Gastric Cancer - Intraperitoneal Chemotherapy - Ovarian Cancer - Primary Peritoneal Cancer
Related subjects » Oncology & Hematology
Table of contents Introduction.-Current chemotherapy of ovarian cancer.-Principals of intraperitoneal chemotherapy.-Phase III trials of intraperitoneal chemotherapy for ovarian cancer.-Criteria for using intraperitoneal chemotherapy for advanced ovarian cancer.-Selection and placement of intraperitoneal catheters for chemotherapy of ovarian cancer.-Selection of drugs for intraperitoneal chemotherapy for ovarian cancer.- Administration guidelines for intraperitoneal chemotherapy for ovarian cancer.-Novel drugs for intraperitoneal therapy for ovarian cancer.-Quality of live evaluations of ovarian cancer intervention studies.
Authors & Editors
Prof. Alberts is Director of the Arizona Cancer Center in Tucson, AZ. He led a workshop on intraperitoneal chemotherapy in January 2006 at the Gynecologic Oncology Group meeting with 400 oncologists and nurses present. He also published the results of the first ever phase III trial comparing IV to IP chemotherapy in the New England Journal of Medicine.